Angiology
Enrollment complete in international drug-eluting stent clinical trial
Published in Hematology Week, December 19th, 2005
SPIRIT II is a 300-patient, randomized clinical trial evaluating XIENCE V, an everolimus-eluting coronary stent system utilizing Guidant's cobalt chromium rapid-exchange MULTI-LINK VISION coronary stent system platform. This single-blind, prospective, randomized, noninferiority study further evaluates the XIENCE V compared to the TAXUS Express 2 paclitaxel-eluting coronary stent system for the treatment of coronary artery disease. Results of the SPIRIT II study will provide additional clinical data to support the launch of XIENCE V in several...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
Source: Hematology Week (2005-12-19)
More Articles from Hematology Week
- Bioterrorism
Multiplex PCR microarray assay screens multiple bioterror pathogens in blood - Blood Safety
Nucleic acid amplification tests screen out blood donors with West Nile virus in U.S. - Hematology
Hematopoiesis is normal when growth hormone is severely deficient - Stem Cell Transplantation
Two activating donor KIRs protects against leukemic relapse after related HLA-identical HSCT - Tissue Engineering
Bone marrow stromal cells are an alternative cell source for tissue-engineered bladder - Angiology
Findings in angiology provide new insights - More from this issue of Hematology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
